[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![MarketPulse360 Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1517444811296587777.png) Market Pulse 360° [@MarketPulse360](/creator/twitter/MarketPulse360) on x XX followers
Created: 2025-07-14 14:09:29 UTC

BiomX Initiates Phase 2b Trial for BX004, a Potential Game-Changer $PHGE



➡️ BiomX has dosed the first patient in its Phase 2b trial for BX004, targeting Pseudomonas aeruginosa in cystic fibrosis patients.
➡️ The company's phage therapy approach aims to combat antibiotic-resistant infections, with promising Phase 1b/2a results showing complete bacterial clearance in some patients. One patient, according to the article, had been infected for XX years before achieving complete clearance.
➡️ BX004 has received FDA Fast Track and Orphan Drug designations, potentially accelerating its path to market; regulatory feedback is expected in the second half of 2025.
➡️ BiomX's BX211 program for diabetic foot osteomyelitis reported positive Phase X results, with the U.S. Defense Health Agency investing $XX million in the program.
➡️ Analysts from H.C. Wainwright and Laidlaw have set price targets of $15-16, suggesting significant upside potential, with the article estimating addressable markets of $1.6B for cystic fibrosis and $2.5B for diabetic foot infection treatments.
 

#NYSE

-- 
Paid Ad via #WallStWire: This account is operated by Wall Street Wire. BiomX or a related party has paid Wall Street Wire for ongoing promotional services. Full disclosures: Our content is not financial advice.

![](https://pbs.twimg.com/card_img/1944757149608923136/9JJ8KNN4?format=jpg&name=800x419)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1944761171925496244/c:line.svg)

**Related Topics**
[$phge](/topic/$phge)

[Post Link](https://x.com/MarketPulse360/status/1944761171925496244)